Courtney D. DiNardo, MD, clinical researcher in the Department of Leukemia, Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center, discusses how potential doublet and triplet combination treatments may work in patients with IDH1-mutated acute myeloid leukemia (AML). DiNardo explains that the next step is determining the proper regimens that yield the best results for patients.

Click here to learn more.